Bruno Montanari
Director/Board Member at BIOTECH ACQUISITION COMPANY
Network origin in Bruno Montanari first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
14
| Public Company | Pharmaceuticals: Other | 14 |
Omnes Capital SAS /Venture/
 Omnes Capital SAS /Venture/ Investment ManagersFinance Omnes Capital SAS /Venture/ is a Venture Capital firm, a subsidiary of Omnes Capital SAS founded in 1999. Omnes Capital /Venture/ is headquartered in Paris.
11
| Operating Division | Investment Managers | 11 |
Horama SA
 Horama SA BiotechnologyHealth Technology Horama SA engages in the development of gene therapies, It focuses on ophthalmological diseases for preserving visual autonomy of patients. The company was founded by Denis Cayet, Christian Hamel, Guylene Le Meur, Philippe Moullier, Vasiliki Kalatzis, and Michel Weberin March 2014 and is headquartered in Paris, France.
11
| Holding Company | Biotechnology | 11 |
Seroba BioVentures Ltd.
 Seroba BioVentures Ltd. Investment ManagersFinance Seroba BioVentures Ltd (Seroba BioVentures) is a venture capital subsidiary of Kernel Management Partners Ltd founded in 2001 by Peter Sandys and Seamus O''Hara. The firm is headquartered in Dublin, Ireland.
9
| Subsidiary | Investment Managers | 9 |
| Private Company | Financial Conglomerates | 7 | |
Complix NV
 Complix NV Pharmaceuticals: MajorHealth Technology Complix NVengages in the development of biopharmaceutical company developing Alphabodies, a pipeline of transformative protein therapeutics. The Company is currently focusing its internal research and development activities on oncology and autoimmune diseases. Its therapeutic Alphabodies focuses on the treatment of autoimmune diseases, such as rheumatoid arthritis, psoriasis and multiple sclerosis, and infectious diseases, and viral diseases such as influenza, HIV, and RSV. The company was founded by Mark Vaeck and Ignace Lasters in 2008 and is headquartered in Diepenbeek, Belgium.
7
| Holding Company | Pharmaceuticals: Major | 7 |
Xention Pharma Ltd.
 Xention Pharma Ltd. Pharmaceuticals: MajorHealth Technology Xention Pharma Ltd. develops and researches drugs. The firm develops novel therapies for the treatment of atrial fibrillation; modulators of IKur and IKACh for atrial fibrillation. The company was founded by John W. Word and is headquartered in Newmarket, the United kingdom.
7
| Holding Company | Pharmaceuticals: Major | 7 |
Atlas Venture SARL
4
| Extinct | Investment Managers | 4 |
Xention Ltd.
 Xention Ltd. Pharmaceuticals: MajorHealth Technology Part of Xention Pharma Ltd., Xention Ltd. is a British company that develops and researches drugs. The company is based in Newmarket, UK. Xention was founded in 2002.
2
| Subsidiary | Pharmaceuticals: Major | 2 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Bruno Montanari via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
| ABLYNX | Biotechnology | Director/Board Member Chief Executive Officer Chief Tech/Sci/R&D Officer Corporate Officer/Principal Corporate Officer/Principal | |
Travecta Therapeutics Pte Ltd.
 Travecta Therapeutics Pte Ltd. Packaged SoftwareTechnology Services Travecta Therapeutics Pte Ltd. develops a novel chemistry platform for delivery of therapies to the brain. The company was founded by David L. Silver, Mahmood Ahmed, Michael Shleifer and Laurent Benissan and is headquartered in Singapore. | Packaged Software | Director/Board Member Founder President Director/Board Member | |
Sprim Ventures Pte Ltd.
 Sprim Ventures Pte Ltd. Investment ManagersFinance Sprim Ventures Pte Ltd (Sprim Ventures) is a venture capital firm founded by Michael Shleifer, Ivan Jarry and Laurent Benissan in 2015. The firm is headquartered in Singapore. | Investment Managers | Private Equity Investor Founder Founder Director of Finance/CFO | |
| Sprim Global Investments Pte Ltd. | Corporate Officer/Principal Founder Founder Director of Finance/CFO | ||
SPRIM
 SPRIM Medical/Nursing ServicesHealth Services SPRIM provides health prevention research and information consulting services. It offers research and clinical services, health marketing and communications, issue and quality management, and regulatory and scientific affairs services. The company was founded by Michael Shleifer, Ivan Jarry and Olivier Shleifer and is headquartered in Paris, France. | Medical/Nursing Services | Corporate Officer/Principal Founder Founder Director of Finance/CFO | |
| Université Libre de Bruxelles | College/University | Undergraduate Degree Doctorate Degree Corporate Officer/Principal Graduate Degree | |
Kernel Management Partners Ltd.
 Kernel Management Partners Ltd. Investment ManagersFinance Kernel Management Partners Ltd. (Kernel Capital) is a venture capital firm founded in 1999 by Niall Olden. The firm is headquartered in Cork, Ireland. | Investment Managers | Private Equity Investor Private Equity Investor Private Equity Investor Private Equity Analyst | |
| University of Utrecht | College/University | Corporate Officer/Principal Doctorate Degree Graduate Degree Doctorate Degree | |
| Sciences Po | College/University | Graduate Degree Undergraduate Degree Graduate Degree | |
| University College Dublin | College/University | Undergraduate Degree Undergraduate Degree Undergraduate Degree | |
| University of London | College/University | Undergraduate Degree Graduate Degree Doctorate Degree | |
Fujirebio Europe NV
 Fujirebio Europe NV Medical SpecialtiesHealth Technology Fujirebio Europe NV develops and markets diagnostic products to improve therapy management and patient health. It focuses on molecular diagnostics and multiparameter testing. The firm also provides LUMIPULSE G1200, an automated chemiluminescent enzyme immunoassay system; LUMIPULSE G600 II, an automated benchtop CLEIA system, routine and novel markers for the oncology sector. The company was founded in 1985 by Philippe Leboulch and is headquartered in Ghent, Belgium. | Medical Specialties | Director/Board Member Corporate Officer/Principal Director/Board Member | |
Asceneuron SA
 Asceneuron SA Pharmaceuticals: MajorHealth Technology Asceneuron SA operates as a biotechnology company. It develops therapeutics for orphan tauopathis and Alzheimer?s disease. The firm specializes in small molecule drug discovery for neurodegenerative diseases. The company was founded by Dirk Beher, Frank Murdoch Armstrong and Christoph Wiessner in October 2012 and is headquartered in Lausanne, Switzerland. | Pharmaceuticals: Major | Director/Board Member Chairman Director/Board Member | |
| University of Bristol | College/University | Undergraduate Degree Undergraduate Degree Undergraduate Degree | |
Amakem NV
 Amakem NV Medical/Nursing ServicesHealth Services Amakem NV operates as a biopharmaceutical company. It uses kinase inhibitors for treatments of bowel, eye, and lung diseases. The company was founded by Jack Elands, Dirk Leysen, Olivier Raynald Defert, and Nadya Kaval on July 22, 2009 and is headquartered in Diepenbeek, Belgium. | Medical/Nursing Services | Director/Board Member Director/Board Member Director/Board Member | |
| MERUS N.V. | Biotechnology | Director/Board Member Director/Board Member | |
| University of Oxford | College/University | Doctorate Degree Undergraduate Degree | |
Minoryx Therapeutics SL
 Minoryx Therapeutics SL BiotechnologyHealth Technology Minoryx Therapeutics SL engages in the development of drugs for the orphan genetic diseases of the central nervous system. The company was founded by Marc Martinell, Joan Aymami, Nigel Ten Fleming and Xavier Barril in 2011 and is headquartered in Barcelona, Spain. | Biotechnology | Director/Board Member Director/Board Member | |
Roche Innovation Center Copenhagen A/S
 Roche Innovation Center Copenhagen A/S Pharmaceuticals: MajorHealth Technology Roche Innovation Center Copenhagen A/S discovers and develops drugs for the treatment of oncology, metabolic diseases, and infectious diseases. The firm manufactures a pipeline of drug candidates that act selectively on disease-related ribonucleic acid to provide patients with novel treatments for both rare and common diseases. It produces pre-clinical and clinical assets for the treatment of a range of diseases including oncology, metabolic diseases, and infectious diseases. The company was founded by Matts Lundwall and Mikael Ørum on January 1, 1998 and is headquartered in Horsholm, Denmark. | Pharmaceuticals: Major | Chief Executive Officer Chief Executive Officer | |
Biotechnology Innovation Organization
 Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
Ventech SA
 Ventech SA Investment ManagersFinance Ventech SA is part of the venture capital arm and a wholly-owned subsidiary of Natixis Private Equity (NPE), which in turn is a subsidiary of Paris-based Natixis SA (XP: KN). Ventech was established in 1998 and is located in Paris. The firm specializes in technology venture capital investing. Ventech manages venture capital funds for a clientele of European institutional investors, with NPE as their sponsor. The firm relies on international strategic alliances with seeding funds and venture capital firms in Germany, Switzerland, Israel, Japan and the US. | Investment Managers | Private Equity Investor Private Equity Analyst | |
Biosensia Ltd.
 Biosensia Ltd. Packaged SoftwareTechnology Services Biosensia Ltd. develops multiplexing point of care in vitro diagnostics platform. It offers RapiPlex, a point-of-care diagnosis system based on a set of proprietary technologies capable of producing quantitative and qualitative laboratory quality test results. The company was founded by Gareth Redmond and Gabriel Crean in 2009 and is headquartered in Dublin, Ireland. | Packaged Software | Director/Board Member Director/Board Member | |
eTheRNA immunotherapies NV
 eTheRNA immunotherapies NV BiotechnologyHealth Technology eTheRNA immunotherapies NV develops novel immunotherapies to overcome cancers and infectious diseases. The company was founded by Carlo Heirman, Kris Thielemans and Sonja van Meirvenne in January 21, 2013 and is headquartered in Niel, Belgium. | Biotechnology | Director/Board Member Director/Board Member | |
PrecisionBiotics Group Ltd.
 PrecisionBiotics Group Ltd. Pharmaceuticals: GenericHealth Technology PrecisionBiotics Group Ltd. operates as a healthcare company. It focuses on isolation, characterization, clinical evaluation, and formulation of unique bacterial strain and actives for inflammatory and infectious conditions. The company was founded by Barry Kiely in 1999 and is headquartered In Cork, Ireland. | Pharmaceuticals: Generic | Director/Board Member Director/Board Member | |
| GALAPAGOS NV | Biotechnology | Director/Board Member Director/Board Member | |
| ADOCIA | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| Université Catholique de Louvain | College/University | Doctorate Degree Corporate Officer/Principal | |
BioVex, Inc.
 BioVex, Inc. Pharmaceuticals: MajorHealth Technology BioVex, Inc. develops vaccines for the treatment of cancer and the prevention of chronic infectious diseases. Its products include OncoVEX oncolytic and ImmunoVEX technology. The company was founded in 1999 by Dr. Robert Coffin and is headquartered in Woburn, MA. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| INSEAD | College/University | Masters Business Admin Doctorate Degree | |
BioVex Group, Inc.
 BioVex Group, Inc. BiotechnologyHealth Technology BioVex Group, Inc. operates as a clinical-stage biotechnology company. It focuses on the development and commercialization of targeted treatments for cancer and the prevention of infectious disease. The company was founded in 1999 and is headquartered in Woburn, MA. | Biotechnology | Director/Board Member Director/Board Member | |
iTeos Therapeutics SA
 iTeos Therapeutics SA Pharmaceuticals: MajorHealth Technology iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium. | Pharmaceuticals: Major | Chairman Director/Board Member | |
Covagen AG
 Covagen AG BiotechnologyHealth Technology Covagen AG engages in the research in as well as development, production, and distribution of pharmaceutical and diagnostic products and technologies. The company was founded by Julian Bertschinger and Dragan Grabulovski in 2007 and is headquartered in Zug, Switzerland. | Biotechnology | Director/Board Member Director/Board Member | |
AgomAb Therapeutics NV
 AgomAb Therapeutics NV Miscellaneous Commercial ServicesCommercial Services AgomAb Therapeutics NV operates as a Belgian biotherapeutics company, developing agonistic antibodies for regeneration of damaged tissues. The company was founded by Paolo Michieli, Manuela Cazzanti, Virginia Morello, Federica Caterina Linty, Michael Potter Saunders, and Hans J. W. de Haard in 2017 and is headquartered in Ghent, Belgium. | Miscellaneous Commercial Services | Founder Director/Board Member | |
| École Centrale Paris | College/University | Undergraduate Degree Graduate Degree | |
Eye Tech Care SA
 Eye Tech Care SA Medical SpecialtiesHealth Technology Eye Tech Care SA develops medical devices for non-invasive eye disease treatment. It offers an ultrasound device which offers a non-invasive treatment that utilizes the ultrasound circular cyclo-coagulation procedure that reduces the intraocular pressure in refractory glaucoma. The firm serves the ophthalmology market in France and Europe. The company was founded by Fabrice Romano, Laurent Farcy and Philippe Chapuis in 2008 and is headquartered in Rillieux-la-Pape, France. | Medical Specialties | Director/Board Member Director/Board Member | |
Aelin Therapeutics NV
 Aelin Therapeutics NV Pharmaceuticals: MajorHealth Technology Aelin Therapeutics NV develops drugs for antibiotics and first-in-class therapeutics. The company is based in Leuven, Belgium. The Belgian company was founded in 2017. The CEO is Els Beirnaert. | Pharmaceuticals: Major | Director/Board Member Chairman | |
InteRNA Technologies BV
 InteRNA Technologies BV BiotechnologyHealth Technology InteRNA Technologies BV develops RNA technologies and applications. It provides drug discovery and development services for the treatment of cancer based on the proprietary microRNA (miRNA) functions. The company develops miRNA-based therapeutics that control genes connected in signal transduction pathways and biological processes as a part of cancer initiation, progression and metastasis. InteRNA Technologies was founded by Edwin Cuppen and Eugene Berezikov in December 2006 and is headquartered in Nijmegen, the Netherlands. | Biotechnology | Director/Board Member Chairman | |
Goldman Sachs & Co. LLC
 Goldman Sachs & Co. LLC Investment Banks/BrokersFinance Goldman Sachs & Co. LLC (GS&Co.) is a securities brokerage firm headquartered in New York City. Founded in 1927, the firm is a subsidiary of The Goldman Sachs Group, Inc. (NYSE: GS). GS&Co. provides services to help hedge funds manage risk, monitor portfolios, maintain liquidity and build their businesses. They offer clients access to global equity and derivatives markets, as well as foreign exchange, commodities, European Lefts, rates and credit across the Americas, Europe and Asia. The firm proactively monitors capital markets, searching for pockets of liquidity and news that may require changes to those strategies. Integration with the Goldman Sachs network gives clients access to the firm's sectored block trades and their insights into price discovery. Their electronic trading program provides clients with tools to manage their trades from pre-trade analytics to post-trade analysis. | Investment Banks/Brokers | Corporate Officer/Principal Corporate Officer/Principal | |
| UCD Michael Smurfit Graduate School of Business | College/University | Undergraduate Degree Graduate Degree | |
Enterome SA
 Enterome SA Pharmaceuticals: MajorHealth Technology Enterome SA develops personalized medical-tests and diagnostics. The firm profiles human gut microbiome to improve management of microbiome-related disease. It primarily specializes in research adn development focusing on disease management. The company was founded by Stanislav Dusko Ehrlich in 2012 and is headquartered in Paris, France. | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal | |
Exevir Bio BV
 Exevir Bio BV Pharmaceuticals: MajorHealth Technology Exevir Bio BV is engaged in biotechnology services. The company is headquartered in Zwijnaarde, Belgium. | Pharmaceuticals: Major | Director/Board Member Chairman | |
Aelix Therapeutics SL
 Aelix Therapeutics SL BiotechnologyHealth Technology Aelix Therapeutics SL researches and develops therapies for HIV. It develops therapeutic vaccines and immunotherapies to treat HIV infection. The firm is a spin-off of HIVACAT, the Catalan project for the development of effective vaccines against HIV. The company was founded by Christian Brander, Bonaventura Clotet, Josep Maria Gatell and Jordi Naval is headquartered in Barcelona, Spain. | Biotechnology | Director/Board Member Director/Board Member |
Statistics
International
| Belgium | 12 |
| France | 11 |
| United Kingdom | 7 |
| Netherlands | 6 |
| United States | 6 |
Sectoral
| Health Technology | 28 |
| Consumer Services | 12 |
| Finance | 5 |
| Commercial Services | 4 |
| Technology Services | 3 |
Operational
| Director/Board Member | 428 |
| Corporate Officer/Principal | 131 |
| Private Equity Investor | 59 |
| Chairman | 59 |
| Independent Dir/Board Member | 54 |
Most connected contacts
- Stock Market
- Insiders
- Bruno Montanari
- Company connections
